 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12...28293031323334353637383940» |
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Journal: Switching from other GLP-1 receptor agonists to semaglutide - impact on HbA1c and body weight: A model-based approach. (Pubmed Central) - Aug 21, 2019
Exposure-response modelling suggests that switching to semaglutide from liraglutide, dulaglutide or exenatide extended-release results in further reductions in HbA1c and body weight. Initial slight deterioration in outcome values when switching to semaglutide 0.25 mg could be avoided by initiating semaglutide treatment at a higher dose.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
$MultiBillion #Ozempic @novonordisk in L.A. casting #Nonunion #TVspot to AVOID small #HEALTHCARE contibs & #Union #MinimumWage bargained by #SAGAFTRA workers. CEO @Larsfruergaard funneling 40% of actor wages to #ScamTalentAgent in #40PercentScam. #UnionBusterOfTheDay #AdsGoUnion (Twitter) - Aug 19, 2019
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
New P4 trial, Combination therapy: EmpaSema: Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria (clinicaltrials.gov) - Aug 19, 2019
P4, N=80, Not yet recruiting, Sponsor: Steno Diabetes Center Copenhagen
- | Mounjaro (tirzepatide) / Eli Lilly
Enrollment open: SURPASS-2: A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (clinicaltrials.gov) - Aug 19, 2019
P3, N=1872, Recruiting, Sponsor: Eli Lilly and Company
Initial slight deterioration in outcome values when switching to semaglutide 0.25 mg could be avoided by initiating semaglutide treatment at a higher dose. Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
Enrollment closed, Combination therapy: A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese (clinicaltrials.gov) - Aug 18, 2019
P1, N=80, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, PYY 1562 / Novo Nordisk
Trial completion: A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese (clinicaltrials.gov) - Aug 14, 2019
P1, N=37, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes (clinicaltrials.gov) - Aug 14, 2019
P1, N=100, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || . @novonordisk up, as it reports 10% rise in 2nd-qtr operating profit https://t.co/sarepJxPO3 #Denmark #diabetes #finance #hematology #metabolics #norditropin #ozempic #pharma #saxenda #victoza (Twitter) - Aug 9, 2019
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P1 trial: A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes (clinicaltrials.gov) - Jul 24, 2019
P1, N=100, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity (clinicaltrials.gov) - Jul 23, 2019
P1, N=68, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Enrollment change, Real-world evidence, Real-world: SURE CANADA: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 23, 2019
P=N/A, N=460, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting | N=217 --> 460
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date: SUSTAIN 11: A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (clinicaltrials.gov) - Jul 17, 2019
P3, N=2043, Recruiting, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Active, not recruiting | N=217 --> 460 Trial completion date: Nov 2020 --> Feb 2021
- | Mounjaro (tirzepatide) / Eli Lilly
Enrollment open: A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Jul 16, 2019
P1, N=117, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Nov 2020 --> Feb 2021 Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: Effects of Semaglutide in HIV-Associated Lipohypertrophy (clinicaltrials.gov) - Jul 14, 2019
P2, N=208, Recruiting, Sponsor: Case Western Reserve University
- | Journal: GREATER COMBINED REDUCTIONS IN HBA ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VS COMPARATORS IN TYPE 2 DIABETES. (Pubmed Central) - Jul 11, 2019
Significantly more subjects achieved both ≥1.0% HbA reduction and ≥5.0% weight loss with once-weekly subcutaneous semaglutide treatment vs comparators in the SUSTAIN trials. A dose-dependent effect was observed with semaglutide.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) (clinicaltrials.gov) - Jul 8, 2019
P=N/A, N=325, Active, not recruiting, Sponsor: Novo Nordisk A/S
A dose-dependent effect was observed with semaglutide. Enrolling by invitation --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P1 trial: A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity (clinicaltrials.gov) - Jul 8, 2019
P1, N=68, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: SURE NL: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS) (clinicaltrials.gov) - Jul 7, 2019
P=N/A, N=217, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (clinicaltrials.gov) - Jul 5, 2019
P3, N=400, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) (clinicaltrials.gov) - Jul 5, 2019
P=N/A, N=325, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial completion date: Jul 2020 --> Feb 2020 | Trial primary completion date: Jul 2020 --> Feb 2020
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage (clinicaltrials.gov) - Jun 23, 2019
P2, N=69, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Jul 2020 --> Feb 2020 | Trial primary completion date: Jul 2020 --> Feb 2020 Not yet recruiting --> Recruiting
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: SUSTAIN FORTE: A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (clinicaltrials.gov) - Jun 20, 2019
P3, N=964, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: SUSTAIN FORTE: A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (clinicaltrials.gov) - Jun 18, 2019
P3, N=964, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage (clinicaltrials.gov) - Jun 16, 2019
P2, N=69, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Mounjaro (tirzepatide) / Eli Lilly
New P3 trial: SURPASS-2: A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (clinicaltrials.gov) - Jun 16, 2019
P3, N=1872, Not yet recruiting, Sponsor: Eli Lilly and Company
- |||| Firsocostat (GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
New P2 trial, Monotherapy: Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jun 14, 2019
P2, N=100, Not yet recruiting, Sponsor: Gilead Sciences
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, PYY 1562 / Novo Nordisk
Enrollment closed: A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese (clinicaltrials.gov) - Jun 12, 2019
P1, N=37, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND) (clinicaltrials.gov) - Jun 6, 2019
P=N/A, N=218, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Enrolling by invitation
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, PK/PD data, Journal: A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. (Pubmed Central) - May 31, 2019
P1
Active, not recruiting --> Enrolling by invitation The pharmacokinetic, pharmacodynamic, and safety profiles of semaglutide were similar in Japanese and Caucasian subjects, suggesting that no dose adjustment is required for the clinical use of semaglutide in Japanese subjects.
- | semaglutide SC once-daily (NN9536) / Novo Nordisk
Review, Journal: Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? (Pubmed Central) - May 30, 2019
The primary pharmacodynamic difference between short-acting (i.e. exenatide twice daily, lixisenatide) and long-acting (i.e. albiglutide, dulaglutide, exenatide once weekly, liraglutide, semaglutide) GLP-1 RAs is that short-acting agents primarily delay gastric emptying (lowering postprandial glucose) and long-acting agents affect both fasting glucose (via enhanced glucose-dependent insulin secretion and reduced glucagon secretion in the fasting state) and postprandial glucose (via enhanced postprandial insulin secretion and inhibition of glucagon secretion). Other advantages of long-acting GLP-1 RAs include smaller fluctuations in plasma drug concentrations, improved gastrointestinal tolerability profiles, and simpler, more convenient administration schedules (once daily for liraglutide and once weekly for albiglutide, dulaglutide, the long-acting exenatide formulation and semaglutide), which might improve treatment adherence and persistence.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Presentación de Ozempic (Semaglutide) de administración semanal. Buenos resultados en su pivotales SUSTAIN. Alternativa a tener en cuenta en el control de Hb glicada, reducción de peso y FRCV en pacientes con DM2 @novonordisk @Diabetes_SEMI (Twitter) - May 28, 2019
- | Clinical, Journal, HEOR: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. (Pubmed Central) - May 18, 2019
Other advantages of long-acting GLP-1 RAs include smaller fluctuations in plasma drug concentrations, improved gastrointestinal tolerability profiles, and simpler, more convenient administration schedules (once daily for liraglutide and once weekly for albiglutide, dulaglutide, the long-acting exenatide formulation and semaglutide), which might improve treatment adherence and persistence. Semaglutide represents a cost-effective alternative to other GLP-1 receptor agonist therapies available in Denmark, demonstrating clinical benefits versus dulaglutide, exenatide ER, liraglutide and lixisenatide for the treatment of patients with T2D.
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: FOCUS: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (clinicaltrials.gov) - May 15, 2019
P3, N=1500, Recruiting, Sponsor: Novo Nordisk A/S
Semaglutide represents a cost-effective alternative to other GLP-1 receptor agonist therapies available in Denmark, demonstrating clinical benefits versus dulaglutide, exenatide ER, liraglutide and lixisenatide for the treatment of patients with T2D. Not yet recruiting --> Recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment change, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) (clinicaltrials.gov) - May 15, 2019
P=N/A, N=325, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting N=217 --> 325
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND) (clinicaltrials.gov) - May 15, 2019
P=N/A, N=218, Active, not recruiting, Sponsor: Novo Nordisk A/S
N=217 --> 325 Enrolling by invitation --> Active, not recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK) (clinicaltrials.gov) - May 14, 2019
P=N/A, N=217, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity (clinicaltrials.gov) - May 14, 2019
P1, N=72, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- ||| Mounjaro (tirzepatide) / Eli Lilly
New P1 trial: A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - May 14, 2019
P1, N=117, Not yet recruiting, Sponsor: Eli Lilly and Company
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
New P4 trial: Effect of Empagliflozin and Semaglutide on the Cardiovascular system and Kidneys in patients with type 2 diabetes (EUDRACT) - May 14, 2019
P4, N=120, Ongoing, Sponsor: Aarhus University Hospital
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
#Industria | @novonordisk presenta #Ozempic, el antidiabético "más potente" del mercado. https://t.co/pgOZlQgVOH (Twitter) - May 14, 2019
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (clinicaltrials.gov) - May 10, 2019
P3, N=868, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || LAI287/semaglutide (NN1535) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Awiqli (insulin icodec) / Novo Nordisk
Enrollment closed, Enrollment change: A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together (clinicaltrials.gov) - May 9, 2019
P1, N=30, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=60 --> 30
- |||| Trulicity (dulaglutide) / Eli Lilly
Trial completion: A Study Comparing the Dulaglutide Pen and the Semaglutide Pen (clinicaltrials.gov) - May 7, 2019
P4, N=312, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=60 --> 30 Recruiting --> Completed
- | Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Review, Journal: The Discovery and Development of Liraglutide and Semaglutide. (Pubmed Central) - Apr 30, 2019
Furthermore, the development of an oral formulation for semaglutide may provide individuals with additional benefits in relation to treatment adherence. In addition to T2D, liraglutide is used in the treatment of obesity, while semaglutide is currently under investigation for use in obesity and NASH.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, HEOR, Real-world evidence, Real-world: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial (clinicaltrials.gov) - Apr 29, 2019
P4, N=2250, Recruiting, Sponsor: Novo Nordisk A/S
In addition to T2D, liraglutide is used in the treatment of obesity, while semaglutide is currently under investigation for use in obesity and NASH. Trial completion date: Nov 2021 --> Oct 2022
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New trial, Real-world evidence, Real-world: SURE NL: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS) (clinicaltrials.gov) - Apr 28, 2019
P, N=217, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@novonordisk #yougay #oh #ohoh #ozempic #commercialgay #commercial causing me rage over the #gayness of it to the point I curse you and your ad person cancer painful shitty life forever (Twitter) - Apr 23, 2019
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND) (clinicaltrials.gov) - Apr 18, 2019
P=N/A, N=217, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial completion date: Nov 2021 --> Oct 2022 Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: Apr 2020 --> Dec 2019
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal: Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in subjects with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover trial. (Pubmed Central) - Apr 17, 2019
P1
Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: Apr 2020 --> Dec 2019 Semaglutide treatment did not compromise the counterregulatory glucagon response during experimental hypoglycaemia in subjects with type 2 diabetes.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Retrospective data, Review, Journal: The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. (Pubmed Central) - Apr 12, 2019
This article revealed that semaglutide had a favourable efficacy and safety in treating T2DM patients. It maybe a superior choice for T2DM patients who have obesity or a poor adherence to daily AHAs.